Breast Cancer

A panel of experts compare the toxicity profiles of abemaciclib and ribociclib.

Early data suggest that BLU-222 combined with ribociclib and fulvestrant is safe and tolerable for patients with HR-positive and HER2-negative breast cancer, potentially overcoming resistance to CDK4/6 inhibitors.

The FDA approved SH-105 (Tepylute) prediluted injectable treatment for breast and ovarian cancers. This innovative formulation eliminates the need for complex powder reconstitution, improving safety and patient care.

Patients with stage I HER2-positive breast cancer treated with rastuzumab emtansine (T-DM1) had beneficial long-term outcomes with a 5-year disease-free survival rate of 97%, with the HER2DX score potentially identifying those at higher risk of recurrence.

A Swedish study suggests bariatric surgery may lower breast cancer risk in obese women, particularly those with high insulin levels at baseline.

This study highlights the lack of clear guidelines for breast cancer management in transgender men after chest contouring surgery. While data is limited, the authors suggest adapting existing recommendations for cisgender women and implementing risk management strategies like pre-surgery evaluation and education.

A recent study found that neighborhood deprivation is associated with higher breast cancer death rates for non-Hispanic White women, but not Black women. This suggests factors beyond socioeconomic status contribute to the racial disparity.

The use of a novel digital health platform achieved a 55% reduction in time to treatment among women with a new diagnosis of breast cancer.

Findings from ASCO 2024 suggest deruxtecan (T-DXd) may become a preferred first-line treatment for patients with hormone receptor (HR)-positive, HER2-low metastatic breast cancer that progressed after endocrine therapy.

Patients with breast cancer who participate in a tailored exercise program after surgery have better shoulder function after 1 month compared with those who received usual care.

A large US study showed population-based multigene testing might be a cost-effective way to identify women at risk for breast and ovarian cancer, potentially preventing more cases but raising concerns about generalizability and cost.

A US study found that a commercially available artificial intelligence (AI) algorithm for breast cancer screening produced more false-positives in Black patients and people with denser breasts, highlighting the importance of diverse datasets in training AI algorithms to reduce health care disparities.

Stephanie Graff, MD, concludes the discussion with thoughts on endocrine therapies in development for patients with ER+/HER2- metastatic breast cancer.

A large study finds that obesity and metabolic syndrome raise breast cancer mortality risk, but through different mechanisms. Metabolic syndrome is linked to a specific type of breast cancer, whereas obesity increases risk across all breast cancer subtypes.

A new study has linked racial and ethnic disparities with factors like age, income, and insurance to breast cancer treatment decline. Patients who received all treatments had better survival, highlighting the need for interventions to improve access and reduce disparities.

Disparities in health care systems around the world limit access to effective treatments for advanced breast cancer, especially for people in low- and middle-income countries and marginalized communities. Stronger health systems and social education efforts are necessary to improve outcomes for all patients.

An expert on breast cancer reviews currently available tests for ESR1 mutations and provides clinical insights on best practices for testing.

Stephanie L. Graff, MD, provides an overview of ESR1 mutations in ER+/HER2- metastatic breast cancer, highlighting their prevalence, clinical implications, and challenges.

Trial results from DESTINY-Breast06 indicate the effectiveness of fam-trastuzumab deruxtecan-nxki in delaying disease progression for patients with hormone receptor (HR)–positive and HER2-low metastatic breast cancer who had prior endocrine therapy.

The USPSTF lowered the recommended starting age for mammograms from 50 to 40 years, citing moderate benefits for early detection in this age group. Disparities persist, especially for Black women, highlighting the need for improved access to health care and social support.

The recent FDA approval of Hercessi expands access to a treatment previously burdened by high costs. Hercessi joins the 5 other biosimilars already on the market.

Melatonin showed no benefit for cancer-related fatigue or other symptoms in women with early-stage breast cancer receiving radiotherapy treatment.

Macro-Mediterranean diets for patients with high-risk breast cancer recurrence found no overall reduction, but women who adhered more closely to the diet showed potential benefit.

Young breast cancer survivors without a specific genetic mutation have a lower risk of developing second primary breast cancer within 10 years of diagnosis.

While mammograms are crucial for early detection of breast cancer and can save lives, social determinants of health and health-related social needs create barriers to access, especially for those with financial hardship, lack of transportation, or social isolation.